• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Personalis Inc.

    2/26/26 5:11:47 PM ET
    $PSNL
    Medical Specialities
    Health Care
    Get the next $PSNL alert in real time by email
    S-8 1 d79188ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 26, 2026

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    PERSONALIS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   27-5411038
    (State or other jurisdiction of
    Incorporation or organization)
      (I.R.S. Employer
    Identification No.)

    6600 Dumbarton Circle

    Fremont, California 94555

    (650) 752-1300

    (Address of principal executive offices) (Zip code)

    2019 Equity Incentive Plan

    2019 Employee Stock Purchase Plan

    2020 Inducement Plan

    (Full titles of the plans)

     

     

    Christopher Hall

    President and Chief Executive Officer

    Personalis, Inc.

    6600 Dumbarton Circle

    Fremont, California 94555

    (650) 752-1300

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    Laura Berezin

    Asa Henin

    Allison Peth

    Cooley LLP

    10265 Science Center Dr.

    San Diego, CA 92121

    (858) 550-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

    This Registration Statement on Form S-8 is being filed by the Registrant to register 5,123,794 additional shares of Common Stock reserved for issuance under the Company’s 2019 Equity Incentive Plan, 500,000 additional shares of Common Stock reserved for issuance under the Company’s 2019 Employee Stock Purchase Plan and 350,000 additional shares of Common Stock reserved for issuance under the Company’s 2020 Inducement Plan.

    Pursuant to General Instruction E of Form S-8, the contents of the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on June 20, 2019 (File No.  333-232233), the Registration Statement on Form S-8 filed with the Commission on March 25, 2020 (File No. 333-237386), the Registration Statement on Form S-8 filed with the Commission on May 7, 2020 (File No. 333-238080), the Registration Statement on Form S-8 filed with the Commission on February 25, 2021 (File No. 333-253528), the Registration Statement on Form S-8 filed with the Commission on February 24, 2022 (File No. 333-262998), the Registration Statement on Form S-8 filed with the Commission on February 23, 2023 (File No.  333-269971), the Registration Statement on Form S-8 filed with the Commission on May 15, 2023 (File No. 333-271940), the Registration Statement on Form S-8 filed with the Commission on February 29, 2024 (File No. 333-277489), the Registration Statement on Form S-8 filed with the Commission on February 27, 2025 (File No. 333-285380), and the Registration Statement on Form S-8 filed with the Commission on August 5, 2025 (File No. 333-289267) are hereby incorporated in this Registration Statement by reference to the extent not replaced hereby.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.

    Incorporation of Documents by Reference.

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

    (a) The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Commission on February 26, 2026.

    (b) The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the year ended December  31, 2024 from the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Commission on April 3, 2025.

    (b) The description of the Registrant’s Common Stock filed as Exhibit 4.1 which is contained in a registration statement on Form 8-A filed with the Commission on June 17, 2019 (File No.  001-38943) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description, including Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Commission on February 25, 2021.

    (c) All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, and other portions of documents that are furnished and not filed or are otherwise not incorporated into registration statements pursuant to applicable Commission rules) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    1


    Item 8.

    Exhibits.

     

              Incorporation by Reference
    Exhibit
    Number
      

    Description

       Form    File No.    Exhibit    Filing Date
      4.1    Amended and Restated Certificate of Incorporation of the Registrant.    8-K    001-38943    3.1    6/24/2019
      4.2    Amended and Restated Bylaws of the Registrant.    10-K    001-38943    3.2    2/26/2026
      4.3    Form of common stock certificate of the Registrant.    S-1/A    333-231703    4.1    6/7/2019
      5.1*    Opinion of Cooley LLP.            
     23.1*    Consent of BDO USA, P.C., Independent Registered Public Accounting Firm.            
     23.2*    Consent of Cooley LLP (reference is made to Exhibit 5.1).            
     24.1*    Power of Attorney (reference is made to the signature page hereto).            
     99.1    Personalis, Inc. 2019 Equity Incentive Plan and forms of agreements thereunder.    S-1/A    333-231703    10.2    6/7/2019
     99.2    Personalis, Inc. 2019 Employee Stock Purchase Plan.    S-1/A    333-231703    10.3    6/7/2019
     99.3    Personalis, Inc. 2020 Inducement Plan, as amended    10-K    001-38943    10.4    2/26/2026
    107*    Filing Fee Table            
     
    *

    Filed herewith.

     

    2


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fremont, State of California, on February 26, 2026.

     

    PERSONALIS, INC.
    By:  

    /s/ Aaron Tachibana

      Aaron Tachibana
      Chief Financial Officer and Chief Operating Officer
      (Principal Financial and Accounting Officer)

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Christopher Hall and Aaron Tachibana as his or her true and lawful attorneys-in-fact and agents, with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Name and Signature

      

    Title

     

    Date

    /s/ Christopher Hall

    Christopher Hall

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

      February 26, 2026

    /s/ Aaron Tachibana

    Aaron Tachibana

      

    Chief Financial Officer and Chief Operating Officer

    (Principal Financial and Accounting Officer)

      February 26, 2026

    /s/ Karin Eastham

    Karin Eastham

       Director   February 26, 2026

    /s/ Olivia Bloom

    Olivia Bloom

       Director   February 26, 2026

    /s/ A. Blaine Bowman

    A. Blaine Bowman

       Director   February 26, 2026

    /s/ Woodrow A. Myers, Jr.

    Woodrow A. Myers, Jr., M.D.

       Director   February 26, 2026

    /s/ Lonnie Shoff

    Lonnie Shoff

       Director   February 26, 2026

    /s/ Kenneth Widder

    Kenneth J. Widder, M.D.

       Director   February 26, 2026

     

    3

    Get the next $PSNL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PSNL

    DatePrice TargetRatingAnalyst
    12/2/2025$11.00Equal-Weight
    Morgan Stanley
    5/15/2025$6.00Buy
    Guggenheim
    3/17/2025$8.00Buy
    Canaccord Genuity
    2/6/2023$8.00Hold → Buy
    Needham
    2/6/2023Hold → Buy
    Needham
    2/25/2022$30.00 → $24.00Outperform
    Oppenheimer
    2/25/2022$30.00 → $18.00Buy
    Citigroup
    2/25/2022$50.00 → $38.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PSNL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Myers Woodrow A Jr bought $16,700 worth of shares (10,000 units at $1.67), increasing direct ownership by 62% to 26,116 units (SEC Form 4)

    4 - Personalis, Inc. (0001527753) (Issuer)

    3/5/24 5:15:53 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

    Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests and full year increased nearly 400% to 16,233 tests Secured Medicare coverage for breast and lung cancer surveillance, validating ultrasensitive MRD technology Strong cash position of approximately $240 million provides capital for commercial expansion Full year 2026 revenue guidance of $78 to $80 million, driven by expected growth of approximately 5x for clinical revenue Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025 and recent business highlights and provided financial

    2/26/26 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the TD Cowen 46th Annual Healthcare Conference on Tuesday, March 3, 2026 at the Boston Marriott Copley Place in Boston, MA. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect mini

    2/17/26 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will

    2/12/26 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    SEC Filings

    View All

    SEC Form S-8 filed by Personalis Inc.

    S-8 - Personalis, Inc. (0001527753) (Filer)

    2/26/26 5:11:47 PM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Personalis Inc.

    10-K - Personalis, Inc. (0001527753) (Filer)

    2/26/26 4:11:12 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Personalis, Inc. (0001527753) (Filer)

    2/26/26 4:05:35 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CFO AND COO Tachibana Aaron

    4 - Personalis, Inc. (0001527753) (Issuer)

    2/25/26 6:51:27 PM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form 4 filed by CHIEF MEDICAL OFFICER AND EVP Chen Richard

    4 - Personalis, Inc. (0001527753) (Issuer)

    2/25/26 6:50:15 PM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form 4 filed by SVP and Chief Legal Officer Moore Stephen Michael

    4 - Personalis, Inc. (0001527753) (Issuer)

    2/25/26 6:48:57 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Personalis with a new price target

    Morgan Stanley resumed coverage of Personalis with a rating of Equal-Weight and set a new price target of $11.00

    12/2/25 8:29:48 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Guggenheim initiated coverage on Personalis with a new price target

    Guggenheim initiated coverage of Personalis with a rating of Buy and set a new price target of $6.00

    5/15/25 8:13:23 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Canaccord Genuity initiated coverage on Personalis with a new price target

    Canaccord Genuity initiated coverage of Personalis with a rating of Buy and set a new price target of $8.00

    3/17/25 8:20:27 AM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Financials

    Live finance-specific insights

    View All

    Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will

    2/12/26 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis Reports Third Quarter 2025 Financial Results

    Company Advances "Win-in-MRD" Strategy with Compelling Clinical Trial Data and Increasing Physician Adoption of NeXT Personal® Platform Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2025. The quarter was distinguished by significant operational momentum in its "Win-in-MRD" strategy, headlined by increasing clinical tests delivered and robust clinical evidence generation. Third Quarter 2025 and Recent Business Highlights Accelerated Clinical Adoption: Delivered 4,388 clinical tests, demonstrating robust 26% sequential increase over Q2 2025 and a 364% year-over-year growth fu

    11/4/25 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis to Announce Third Quarter 2025 Financial Results

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shor

    10/21/25 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Personalis Inc.

    SC 13G/A - Personalis, Inc. (0001527753) (Subject)

    8/19/24 6:03:38 AM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Personalis Inc.

    SC 13G - Personalis, Inc. (0001527753) (Subject)

    7/26/24 12:56:21 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by Personalis Inc.

    SC 13D/A - Personalis, Inc. (0001527753) (Subject)

    6/28/24 4:01:17 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Leadership Updates

    Live Leadership Updates

    View All

    Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

    Bhandari to drive regulatory strategies for minimal residual disease (MRD) cancer test Personalis achieves ISO 13485:2016 certification, attesting to its ability to deliver medical devices and related services of the highest quality Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance. With over two decades of industry marketing and regulatory affairs experience, Ms. Bhandari will help the company navigate the regulatory requirements for the NeXT Personal® MRD test. She was most recently VP, Regulatory Affairs at GRAIL, and previously held se

    10/18/23 7:15:00 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Dr. Kenneth J. Widder Joins Personalis Board of Directors

    Personalis, Inc. (NASDAQ:PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporation and Evoke Pharma, Inc. and has over 40 years of experience working with biomedical companies, having previously served as a founder, director and/or CEO of Sydnexis, Inc., OrphoMed, Inc., Sytera, Inc., NovaCardia, Inc., Santarus, Inc., and Molecular Biosystems Inc., and as a general partner at LVP Life Science Ventures (formerly Latterell Venture Partners) and Windamere Venture Partners. He holds an M.D. from Northwestern University and trained in pathology at Duke University. "We are delighted to ha

    6/13/23 7:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis Announces CEO Retirement and Transition

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that John West, co-founder, CEO and member of the board of directors of Personalis, notified the Company of his decision to retire as CEO and a director at the end of the calendar year. Mr. West has served in the DNA sequencing field for over forty years, and co-founded Personalis with four Stanford professors in 2011. Effective December 31, 2022, Aaron Tachibana, Personalis Chief Financial Officer, will serve as interim CEO and Christopher Hall, Personalis SVP and Head, Diagnostics Business, will be promoted to President. Mr. West will continue to serve as an advisor to the Board. "We th

    12/14/22 4:02:00 PM ET
    $PSNL
    Medical Specialities
    Health Care